NeoRecormon

Negara: Uni Eropa

Bahasa: Inggris

Sumber: EMA (European Medicines Agency)

Beli Sekarang

Selebaran informasi Selebaran informasi (PIL)
15-03-2023
Karakteristik produk Karakteristik produk (SPC)
15-03-2023

Bahan aktif:

epoetin beta

Tersedia dari:

Roche Registration GmbH

Kode ATC:

B03XA01

INN (Nama Internasional):

epoetin beta

Kelompok Terapi:

Antianemic preparations

Area terapi:

Kidney Failure, Chronic; Anemia; Cancer; Blood Transfusion, Autologous

Indikasi Terapi:

Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adult and paediatric patients;treatment of symptomatic anaemia in adult patients with non-myeloid malignancies receiving chemotherapy;increasing the yield of autologous blood from patients in a pre-donation programme. Its use in this indication must be balanced against the reported increased risk of thromboembolic events. Treatment should only be given to patients with moderate anaemia (Hb 10 - 13 g/dl [6.21 - 8.07 mmol/l], no iron deficiency) if blood conserving procedures are not available or insufficient when the scheduled major elective surgery requires a large volume of blood (4 or more units of blood for females or 5 or more units for males).

Ringkasan produk:

Revision: 33

Status otorisasi:

Authorised

Tanggal Otorisasi:

1997-07-16

Selebaran informasi

                                48
B. PACKAGE LEAFLET
49
PACKAGE LEAFLET: INFORMATION FOR THE USER
NEORECORMON 500 IU
NEORECORMON 2000 IU
NEORECORMON 3000 IU
NEORECORMON 4000 IU
NEORECORMON 5000 IU
NEORECORMON 6000 IU
NEORECORMON 10,000 IU
NEORECORMON 20,000 IU
NEORECORMON 30,000 IU
SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin beta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
•
Keep this leaflet. You may need to read it again.
•
If you have any further questions, ask your doctor or pharmacist.
•
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs or illness are the same as yours.
•
If you get any side effects, talk to your doctor or pharmacist. This
includes any possible side
effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What NeoRecormon is and what it is used for
2.
What you need to know before you use NeoRecormon
3.
How to use NeoRecormon
4.
Possible side effects
5.
How to store NeoRecormon
6.
Content of the pack and other information
1.
WHAT NEORECORMON IS AND WHAT IT IS USED FOR
NeoRecormon is a clear, colourless solution for injection under the
skin
_(subcutaneously)_
or into a
vein
_(intravenously). _
It contains a hormone called
_epoetin beta_
, which stimulates the production of red
blood cells. Epoetin beta is produced by a specialised genetic
technology and works in exactly the
same way as the natural hormone erythropoietin.
You must talk to your doctor if you do not feel better or if you feel
worse.
NeoRecormon is indicated for:
•
TREATING SYMPTOMATIC ANAEMIA CAUSED BY CHRONIC KIDNEY DISEASE
(renal anaemia) in patients
on dialysis, or not yet on dialysis.
•
PREVENTING ANAEMIA IN PREMATURE INFANTS
(weighing 750 to 1500 g and born at less than
34 weeks).
•
TREATING ANAEMIA WITH RELATED SYMPTOMS IN ADULT CANCER PATIENTS
RECEIVING CHEMOTHERAPY
•
TREATING PEOPLE DONATING THEIR OWN BLOOD BEFORE SURGERY.
The injections of epoetin beta will
increas
                                
                                Baca dokumen lengkapnya
                                
                            

Karakteristik produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
NeoRecormon 500 IU solution for injection in pre-filled syringe
NeoRecormon 2000 IU solution for injection in pre-filled syringe
NeoRecormon 3000 IU solution for injection in pre-filled syringe
NeoRecormon 4000 IU solution for injection in pre-filled syringe
NeoRecormon 5000 IU solution for injection in pre-filled syringe
NeoRecormon 6000 IU solution for injection in pre-filled syringe
NeoRecormon 10,000 IU solution for injection in pre-filled syringe
NeoRecormon 20,000 IU solution for injection in pre-filled syringe
NeoRecormon 30,000 IU solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
NeoRecormon 500 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains 500
international units (IU)
corresponding to 4.15 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 1667 IU epoetin beta.
NeoRecormon 2000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
2000 international units (IU)
corresponding to 16.6 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 6667 IU epoetin beta.
NeoRecormon 3000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
3000 international units (IU)
corresponding to 24.9 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 10,000 IU epoetin beta.
NeoRecormon 4000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution for injection contains
4000 international units (IU)
corresponding to 33.2 micrograms epoetin beta* (recombinant human
erythropoietin).
One ml solution for injection contains 13,333 IU epoetin beta.
NeoRecormon 5000 IU solution for injection in pre-filled syringe
One pre-filled syringe with 0.3 ml solution
                                
                                Baca dokumen lengkapnya
                                
                            

Dokumen dalam bahasa lain

Selebaran informasi Selebaran informasi Bulgar 15-03-2023
Karakteristik produk Karakteristik produk Bulgar 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Bulgar 03-12-2015
Selebaran informasi Selebaran informasi Spanyol 15-03-2023
Karakteristik produk Karakteristik produk Spanyol 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Spanyol 03-12-2015
Selebaran informasi Selebaran informasi Cheska 15-03-2023
Karakteristik produk Karakteristik produk Cheska 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Cheska 03-12-2015
Selebaran informasi Selebaran informasi Dansk 15-03-2023
Karakteristik produk Karakteristik produk Dansk 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Dansk 03-12-2015
Selebaran informasi Selebaran informasi Jerman 15-03-2023
Karakteristik produk Karakteristik produk Jerman 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Jerman 03-12-2015
Selebaran informasi Selebaran informasi Esti 15-03-2023
Karakteristik produk Karakteristik produk Esti 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Esti 03-12-2015
Selebaran informasi Selebaran informasi Yunani 15-03-2023
Karakteristik produk Karakteristik produk Yunani 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Yunani 03-12-2015
Selebaran informasi Selebaran informasi Prancis 15-03-2023
Karakteristik produk Karakteristik produk Prancis 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Prancis 03-12-2015
Selebaran informasi Selebaran informasi Italia 15-03-2023
Karakteristik produk Karakteristik produk Italia 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Italia 03-12-2015
Selebaran informasi Selebaran informasi Latvi 15-03-2023
Karakteristik produk Karakteristik produk Latvi 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Latvi 03-12-2015
Selebaran informasi Selebaran informasi Lituavi 15-03-2023
Karakteristik produk Karakteristik produk Lituavi 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Lituavi 03-12-2015
Selebaran informasi Selebaran informasi Hungaria 15-03-2023
Karakteristik produk Karakteristik produk Hungaria 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Hungaria 03-12-2015
Selebaran informasi Selebaran informasi Malta 15-03-2023
Karakteristik produk Karakteristik produk Malta 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Malta 03-12-2015
Selebaran informasi Selebaran informasi Belanda 15-03-2023
Karakteristik produk Karakteristik produk Belanda 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Belanda 03-12-2015
Selebaran informasi Selebaran informasi Polski 15-03-2023
Karakteristik produk Karakteristik produk Polski 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Polski 03-12-2015
Selebaran informasi Selebaran informasi Portugis 15-03-2023
Karakteristik produk Karakteristik produk Portugis 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Portugis 03-12-2015
Selebaran informasi Selebaran informasi Rumania 15-03-2023
Karakteristik produk Karakteristik produk Rumania 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Rumania 03-12-2015
Selebaran informasi Selebaran informasi Slovak 15-03-2023
Karakteristik produk Karakteristik produk Slovak 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Slovak 03-12-2015
Selebaran informasi Selebaran informasi Sloven 15-03-2023
Karakteristik produk Karakteristik produk Sloven 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Sloven 03-12-2015
Selebaran informasi Selebaran informasi Suomi 15-03-2023
Karakteristik produk Karakteristik produk Suomi 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Suomi 03-12-2015
Selebaran informasi Selebaran informasi Swedia 15-03-2023
Karakteristik produk Karakteristik produk Swedia 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Swedia 03-12-2015
Selebaran informasi Selebaran informasi Norwegia 15-03-2023
Karakteristik produk Karakteristik produk Norwegia 15-03-2023
Selebaran informasi Selebaran informasi Islandia 15-03-2023
Karakteristik produk Karakteristik produk Islandia 15-03-2023
Selebaran informasi Selebaran informasi Kroasia 15-03-2023
Karakteristik produk Karakteristik produk Kroasia 15-03-2023
Laporan Penilaian publik Laporan Penilaian publik Kroasia 03-12-2015

Peringatan pencarian terkait dengan produk ini

Lihat riwayat dokumen